The problem with CYTR is that there may be a lot o
Post# of 22755
On the other hand, if the Board is smart (I am sure we can agree that they are) they might elect to keep the Phase 2b results for Aldoxorubicin under wraps for a couple of reasons: (1) Terrible news which could then push the pps down to say $.10 before the shareholder meeting at which point even an 1-8 reverse split would not get them over the $1.00 pps NASDAQ requirement. But withholding the bad news a little while longer to give them the 10 days to become NASDAQ compliant (hopefully the pps would not tank from say $4.80 (8 x$.60) after split price to below $1.00). - OR - (2) Great news which could help propel the pps upward even at a $4.60 pps after split. Additionally, at this same time, the MM's would be allowed to jump into the pricing frenzy, as most are not allowed to purchase shares at these lower levels. This could be a great win/win for CYTR causing the pps to go from a 1-8 reverse split of say $4.80 ($.60 x , up to a pps of say $7 or $8.
I know,,,I drive myself crazy trying to figure this stuff out.
https://twitter.com/twitter/statuses/957208055766241280